Articles / COVID treatments – where are we?
0 hours
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
0 hours
These are activities that require reflection on feedback about your work.
0 hours
These are activities that use your work data to ensure quality results.
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
These are activities that require reflection on feedback about your work.
These are activities that use your work data to ensure quality results.
There appears to be a myriad of potential treatments for our current health threat – COVID19. But just how real are these options? And which if any of these are likely to make it into our treatment regimens? A review just published online in JAMA gives us a neat summary of where we are up to in terms of treatment.
Firstly, it needs to be understood that ‘no proven effective therapies currently exist’, the review authors state. But despite this depressing reality, the upside is we already know a significant amount of detail about this novel coronavirus and its lifecycle in host cells, which provides scientists many potential targets for treatments. We also have the opportunity to review agents used in the past to treat SARS and MERS, which are similar viruses to COVID-19.
JAMA published online April 13,2020. Doi 10:1001/jama2020.6019
Obstructive Sleep Apnoea & Driving: The GP's Role
Non-Hormonal & Hormonal Options for Hot Flushes
Why is LDL Control Important?
Muscle Health in Chronic Disease: A Practical Guide for GPs
Strongly agree
Slightly agree
slightly disagree
strongly disagree
Listen to expert interviews.
Click to open in a new tab
Browse the latest articles from Healthed.
Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.
Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.
Menopause and MHT
Multiple sclerosis vs antibody disease
Using SGLT2 to reduce cardiovascular death in T2D
Peripheral arterial disease